Octanate Lv (Human Coagulation Factor Viii)

Human Coagulation Factor VIII supplied by Octanate Lv binds to activated factor IX on phospholipid surfaces, forming the intrinsic tenase complex. This complex accelerates the conversion of factor X to factor Xa, leading to thrombin generation and fibrin clot formation, thereby restoring the intrinsic pathway of coagulation that is deficient in hemophilia A.

The dose of Octanate Lv is individualized by the prescribing clinician based on the patient’s body weight, severity of factor VIII deficiency, type of bleed or surgical procedure, and desired target factor VIII activity level. Dosing regimens are established according to clinical guidelines and patient response, and should not be altered without medical advice.

Safety data for Octanate Lv in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case carefully and discuss potential risks with the patient.

To order Octanate Lv, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Octanate Lv is a plasma‑derived factor VIII concentrate, whereas many alternatives are recombinant. Plasma‑derived products contain von Willebrand factor, which may enhance stability, but carry a theoretical risk of pathogen transmission that is mitigated by viral inactivation steps. Recombinant products avoid plasma exposure but may differ in pharmacokinetics. Choice depends on clinical preference, patient history and regulatory considerations.

Octanate Lv must be stored at 2‑8 °C (refrigerated). It should be kept in its original container, protected from light, and must not be frozen or shaken. Maintaining the cold chain is essential to preserve product potency and safety.

Octanate Lv is administered by intravenous infusion. The solution is typically diluted with an appropriate diluent as specified in the product label and infused over a period determined by the prescribing clinician. Administration should be performed by qualified healthcare personnel in a setting equipped to monitor for infusion‑related reactions.

The most serious risks include the development of inhibitory antibodies that neutralize factor VIII activity, severe allergic or anaphylactic reactions, thromboembolic events due to excessive clotting, and the rare possibility of transmission of blood‑borne pathogens despite rigorous viral inactivation processes.

Octanate Lv is contraindicated in patients with known hypersensitivity to plasma‑derived factor VIII products or any of the excipients in the formulation. It should also be avoided in individuals with a history of severe allergic reactions to similar products until a thorough risk‑benefit assessment is performed by a healthcare professional.